The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
 
Vikas Gupta
Honoraria - Incyte; Novartis
Consulting or Advisory Role - Novartis
Research Funding - Gilead Sciences (Inst); Incyte (Inst); Novartis (Inst)
 
Srdan Verstovsek
No Relationships to Disclose
 
Ruben A. Mesa
Honoraria - AOP Orphan Pharmaceuticals; Novartis; shire
Consulting or Advisory Role - Baxalta; Galena Biopharma
Research Funding - CTI (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); NS Pharma (Inst); Pfizer (Inst); Pharmaessentia (Inst); Promedior (Inst)
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Incyte; Novartis
 
Jason R. Gotlib
Honoraria - Incyte
Consulting or Advisory Role - Incyte
 
John F. DiPersio
Honoraria - Dava Oncology; Merck Sharp & Dohme; Sanofi
Consulting or Advisory Role - Boehringer Ingelheim; Fate Therapeutics; GlaxoSmithKline; Idera; Juno Therapeutics; Macrogenics; SERVIER
Research Funding - Amphivena Therapeutics (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Dava Oncology; Fate Therapeutics; GlaxoSmithKline; Idera; Juno Therapeutics; Macrogenics; Merck Sharp & Dohme; Sanofi; SERVIER
 
John V. Catalano
No Relationships to Disclose
 
Michael W.N. Deininger
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis; Pfizer
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Incyte (Inst); Novartis (Inst)
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
 
Carole Brennan Miller
Honoraria - Incyte; Janssen; Novartis
Consulting or Advisory Role - Gilead Sciences; Incyte; Novartis
Speakers' Bureau - Incyte; Novartis
 
Richard T. Silver
Honoraria - AOP Orphan Pharmaceuticals; Pharmaessentia
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Incyte; Pharmaessentia
Expert Testimony - Gerson Lehrman Group
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Pharmaessentia
 
Moshe Talpaz
Consulting or Advisory Role - Ariad; Novartis; Pfizer
Research Funding - Ariad; Incyte; Novartis; Pfizer; Sanofi
Travel, Accommodations, Expenses - ARIAD; Incyte; Novartis; Pfizer
 
Elliott F. Winton
Consulting or Advisory Role - Incyte
 
Jimmie Huling Harvey
Leadership - Fortress Biotech
Stock and Other Ownership Interests - CorMedix; Fortress Biotech; Intrexon; TRACON Pharma; ZIOPHARM Oncology
 
Murat O. Arcasoy
Research Funding - Gilead Sciences (Inst); Incyte (Inst)
 
Elizabeth O. Hexner
No Relationships to Disclose
 
Roger M. Lyons
Employment - Texas Oncology
Leadership - McKesson
Stock and Other Ownership Interests - Texas Oncology
Consulting or Advisory Role - Amgen
 
Ronald Paquette
Honoraria - Incyte
 
Azra Raza
No Relationships to Disclose
 
Deanna Kornacki
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Kang Sun
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Delta-Fly Pharma (Inst); Novartis (Inst); Pfizer (Inst)